Larimar Therapeutics Statistics
Share Statistics
Larimar Therapeutics has 63.81M shares outstanding. The number of shares has increased by 47.44% in one year.
| Shares Outstanding | 63.81M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 37.01M |
| Failed to Deliver (FTD) Shares | 610 |
| FTD / Avg. Volume | 0.08% |
Short Selling Information
The latest short interest is 2.72M, so 4.27% of the outstanding shares have been sold short.
| Short Interest | 2.72M |
| Short % of Shares Out | 4.27% |
| Short % of Float | 7.36% |
| Short Ratio (days to cover) | 3.98 |
Valuation Ratios
The PE ratio is -5.41 and the forward PE ratio is -5.87.
| PE Ratio | -5.41 |
| Forward PE | -5.87 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 2.44 |
| P/FCF Ratio | -5.94 |
| PEG Ratio | n/a |
Enterprise Valuation
Larimar Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 9.49, with a Debt / Equity ratio of 0.
| Current Ratio | 9.49 |
| Quick Ratio | 9.49 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.45% and return on capital (ROIC) is -47.85%.
| Return on Equity (ROE) | -0.45% |
| Return on Assets (ROA) | -0.39% |
| Return on Capital (ROIC) | -47.85% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -879.74K |
| Employee Count | 42 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 45.97% in the last 52 weeks. The beta is 0.71, so Larimar Therapeutics 's price volatility has been higher than the market average.
| Beta | 0.71 |
| 52-Week Price Change | 45.97% |
| 50-Day Moving Average | 7.18 |
| 200-Day Moving Average | 7.81 |
| Relative Strength Index (RSI) | 41.33 |
| Average Volume (20 Days) | 762.55K |
Income Statement
In the last 12 months, Larimar Therapeutics had revenue of $0 and earned -$36.95M in profits. Earnings per share was $-0.84.
| Revenue | 0 |
| Gross Profit | -311.00K |
| Operating Income | -41.76M |
| Net Income | -36.95M |
| EBITDA | -41.45M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.84 |
Balance Sheet
The company has $26.75M in cash and $5.55M in debt, giving a net cash position of $21.20M.
| Cash & Cash Equivalents | 26.75M |
| Total Debt | 5.55M |
| Net Cash | 21.20M |
| Retained Earnings | -188.55M |
| Total Assets | 219.02M |
| Working Capital | 196.97M |
Cash Flow
In the last 12 months, operating cash flow was -$33.46M and capital expenditures -$164.00K, giving a free cash flow of -$33.62M.
| Operating Cash Flow | -33.46M |
| Capital Expenditures | -164.00K |
| Free Cash Flow | -33.62M |
| FCF Per Share | -0.77 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
LRMR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -13.64% |
| FCF Yield | -8.55% |
Analyst Forecast
The average price target for LRMR is $19, which is 208.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $19 |
| Price Target Difference | 208.4% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on May 29, 2020. It was a backward split with a ratio of 1:12.
| Last Split Date | May 29, 2020 |
| Split Type | backward |
| Split Ratio | 1:12 |
Scores
| Altman Z-Score | 10.5 |
| Piotroski F-Score | 1 |